ReviewJournal of clinical and experimental hepatology
Management of Portal Hypertension.
Review in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 31 citations in OpenAlex.
- Addition of midodrine to albumin reduces the incidence of complications of large-volume paracentesis: an RCT comparing midodrine, terlipressin, and albumin.Hepatology international · 2025Trial
- Albumin-to-creatinine ratio as non-invasive marker for prediction of non- bleeding esophageal varices. a cross-sectional observational study.BMC gastroenterology · 2026Observational
- Soluble endoglin as a marker of clinically significant portal hypertension in patients with cirrhosis.Scientific reports · 2026Article
- Impact of clinically significant portal hypertension on posthepatectomy liver failure: A systematic review and meta-analysis.World journal of hepatology · 2026Article
- Endohepatology: Evolving Indications, Challenges, Unmet Needs and Opportunities.Gastro hep advances · 2026Review
- Variceal Upper Gastrointestinal Bleeding: A Retrospective Cohort of 98 Cases, Historical Comparison, and Updated Management Algorithm.Life (Basel, Switzerland) · 2025Article
- Clinical significance of transjugular intrahepatic portosystemic shunting for hepatocellular carcinoma complicated with portal hypertension.Journal of gastrointestinal oncology · 2025Article
- Assessing portal hypertension and its impact on carbon emissions.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2025Article
- Analysis and mining of L-ornithine L-aspartate adverse events based on FAERS database.Scientific reports · 2025Article
- [Effects of ascites grading and the application of non-selective beta-blockers on the 1-year prognosis of acute-on-chronic liver failure].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Article
- Standard technique in Japan for measuring hepatic venous pressure gradient.Journal of gastroenterology · 2025Review
- Etiologies of Splenic Venous Hypertension: A Review.Journal of clinical and translational hepatology · 2024Review
- Thyroxine Levels Predict the Development of Brain Failure in Patients With Cirrhosis in Indian Population.Gastro hep advances · 2024Review
- Drivers of cardiovascular disease in metabolic dysfunction-associated steatotic liver disease: the threats of oxidative stress.Frontiers in cardiovascular medicine · 2024Review
- Portal Hypertension among Patients with Chronic Liver Disease Admitted to the Department of Internal Medicine of a Tertiary Care Centre.JNMA; journal of the Nepal Medical Association · 2023Article
- Updates in noncirrhotic portal hypertension.Clinical liver disease · 2023Article
- Bleeding risk and thrombosis in cirrhosis: a paradox with a need to address them.Hepatobiliary surgery and nutrition · 2023Article
- Pharmacotherapies for Portal Hypertension: Current Status and Expanding Indications.Current hepatology reports · 2023Article
- Pathophysiology and management of liver cirrhosis: from portal hypertension to acute-on-chronic liver failure.Frontiers in medicine · 2023Review
- Early Experience with Surgical Management of Non-Cirrhotic Portal Hypertension in Nigeria: Report from a Single Centre.Journal of the West African College of SurgeonsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Portal hypertension is the cause of the clinical complications associated with cirrhosis. The primary complications of portal hypertension are ascites, acute variceal bleed, and hepatic encephalopathy. Hepatic venous pressure gradient measurement remains the gold standard test for diagnosing cirrhosis-related portal hypertension. Hepatic venous pressure gradient more than 10 mmHg is associated with an increased risk of complications and is termed clinically significant portal hypertension (CSPH). Clinical, laboratory, and imaging methods can also aid in diagnosing CSPH non-invasively. Recently, deep learning methods have been demonstrated to diagnose CSPH effectively. The management of portal hypertension is always individualized and is dependent on the etiology, the availability of therapies, and the degree of portal hypertension complications. In this review, we discuss the diagnosis and management of cirrhosis-related portal hypertension in detail. Also, we highlight the history of portal hypertension and future research areas in portal hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.